期刊
ANNALS OF THE RHEUMATIC DISEASES
卷 81, 期 11, 页码 1491-1503出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/ard-2022-222405
关键词
antirheumatic agents; arthritis; rheumatoid; therapeutics; tumor necrosis factor inhibitors
类别
资金
- Pfizer
This study aimed to characterize infections in patients with rheumatoid arthritis (RA) receiving different treatment regimens. The results showed that tofacitinib had a higher risk of infections compared to tumor necrosis factor inhibitors (TNFi). These findings may provide insights for future treatment decisions.
Objectives To characterise infections in patients with rheumatoid arthritis (RA) in ORAL Surveillance. Methods In this open-label, randomised controlled trial, patients with RA aged >= 50 years with >= 1 additional cardiovascular risk factor received tofacitinib 5 or 10 mg two times per day or a tumour necrosis factor inhibitor (TNFi). Incidence rates (IRs; patients with first events/100 patient-years) and hazard ratios (HRs) were calculated for infections, overall and by age (50-<65 years; >= 65 years). Probabilities of infections were obtained (Kaplan-Meier estimates). Cox modelling identified infection risk factors. Results IRs/HRs for all infections, serious infection events (SIEs) and non-serious infections (NSIs) were higher with tofacitinib (10>5 mg two times per day) versus TNFi. For SIEs, HR (95% CI) for tofacitinib 5 and 10 mg two times per day versus TNFi, respectively, were 1.17 (0.92 to 1.50) and 1.48 (1.17 to 1.87). Increased IRs/HRs for all infections and SIEs with tofacitinib 10 mg two times per day versus TNFi were more pronounced in patients aged >= 65 vs 50-<65 years. SIE probability increased from month 18 and before month 6 with tofacitinib 5 and 10 mg two times per day versus TNFi, respectively. NSI probability increased before month 6 with both tofacitinib doses versus TNFi. Across treatments, the most predictive risk factors for SIEs were increasing age, baseline opioid use, history of chronic lung disease and time-dependent oral corticosteroid use, and, for NSIs, female sex, history of chronic lung disease/infections, past smoking and time-dependent Disease Activity Score in 28 joints, C-reactive protein. Conclusions Infections were higher with tofacitinib versus TNFi. Findings may inform future treatment decisions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据